Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — Q3 FY2019 Earnings Presentation
13 slides from Cencora's earnings presentation, Aug 1, 2019
Slide 1: Q3 FY2019 Financial Results
Q3 FY2019 Financial Results August 1, 2019
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "ou
Slide 3: AmerisourceBergen is united in our responsibility to create healthier futures
AmerisourceBergen is united in our responsibility to create healthier futures. AmerisourceBergen drives innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain. 3
Slide 4: Q3 FY2019 Financial Results: Overview
Q3 FY2019 Financial Results: Overview Continued Strong • Raising adjusted diluted EPS guidance range to $7.00 to $7.10 Performance in Fiscal (up from $6.70 to $6.90) • Well-positioned heading into the fourth quarter 2019 Third Quarter • Solid results driven by strong specialty product sales, growth
Slide 5: Q3 FY2019 Financial Results
Q3 FY2019 Financial Results Adjusted GAAP (non-GAAP)1 Revenue $45.2B $45.2B % Change (Year-over-Year) 4.9% 4.9% Gross Profit $1.2B $1.2B % Change 1.6% 4.9% Operating Expenses $825M $723M % Change 0.3% 3.7% Operating Income $407M $507M % Change 4.5% 6.8% Interest Expense, Net $36M $36M % Change (23.8
Slide 6: Pharmaceutical Distribution Services Segment Results
Q3 FY2019 Financial Results: Pharmaceutical Distribution Services Segment Q3 FY2019 Q3 FY2018 Revenue $43.5B $41.6B Operating Income $411.7M $392.7M Percentages of Revenue Gross Profit 2.08% 2.07% Operating Expenses 1.13% 1.13% Operating Income 0.95% 0.94% ▪ Revenue increase primarily due to continu
Slide 7: Other – Global Commercialization Services & Animal Health
Q3 FY2019 Financial Results: Other – Global Commercialization Services & Animal Health Q3 FY2019 Q3 FY2018 Revenue $1.7B $1.6B Operating Income $95.1M $82.3M Percentages of Revenue Gross Profit 18.77% 19.40% Operating Expenses 13.29% 14.25% Operating Income 5.48% 5.15% ▪ Other includes MWI, World Co
Slide 8: Differentiated and positioned for growth
Differentiated and positioned for growth Customer Base Innovative Services & • Key anchor customers Solutions • Fast growing • Customer-focused offerings • U.S. Pharmaceutical focus serving manufacturers and provider customers Leadership in Specialty Successful Financial Distribution & Services Stew
Slide 9: FY19 Financial Guidance
FY19 Financial Guidance Expectations on an Adjusted (non-GAAP) Basis(1),(2) Revenue Mid-single digit percent growth Diluted Earnings Per Share $7.00 to $7.10 Operating Expense Mid-single digit percent growth Operating Income 3% to 4% growth Pharmaceutical Distribution Services 2% to 3% growth Operat
Slide 10: Appendix
Appendix N) AmerisourceBergen’
Slide 11: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 11
Slide 12: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 12
Slide 13: AmerisourceBergen: Where knowledge, reach and partnership shape healthcare delivery
N) AmerisourceBergen’ Where knowledge, reach and partnership shape healthcare delivery.